Corcept Therapeutics shares are trading higher after Truist Securities reiterated a Buy rating on the stock and raised its price target from $44 to $65.
Portfolio Pulse from Benzinga Newsdesk
Corcept Therapeutics shares are trading higher after Truist Securities reiterated a Buy rating on the stock and raised its price target from $44 to $65.
June 04, 2024 | 5:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Corcept Therapeutics shares are trading higher following Truist Securities' reiteration of a Buy rating and an increase in the price target from $44 to $65.
The reiteration of a Buy rating and a significant increase in the price target by Truist Securities is a strong positive signal for investors, likely driving the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100